HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Di Florio, A. Articles by Sette, C. Search for Related Content PubMed PubMed Citation Articles by Di Florio, A. Articles by Sette, C.

¹ Department of Public Health and Cell Biology, University of Rome Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
² Digestive and Liver Disease Unit, II Medical School, University of Rome La Sapienza, Rome, Italy
³ Institute of experimental Neuroscience, IRCCS Fondazione Santa Lucia, Rome, Italy

(Requests for offprints should be addressed to G D Fave who is now at Digestive and Liver Disease Unit, II Medical School, University of Rome La Sapienza, Rome, Italy; Email: gianfranco.dellefave{at}uniroma1.it); C Sette is now at Department of Public Health and Cell Biology, University of Rome Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy

Pancreatic endocrine tumours (PETs) are rare and ‘indolent’ neoplasms that usually develop metastatic lesions and exhibit poor response to standard medical treatments. Few studies have investigated pathways responsible for PET cell growth and invasion and no alternative therapeutic strategies have been proposed. In a recent microarray analysis for genes up-regulated in PETs, we have described the up-regulation of soluble Src family tyrosine kinases in this neoplasia, which may represent potentially promising candidates for therapy. Herein, we have investigated the expression and function of Src family kinases in PETS and PET cell lines. Western blot analysis indicated that Src is highly abundant in the PET cell lines CM and QGP-1. Immunohistochemistry and Western blot analyses showed that Src is up-regulated also in human PET lesions. Pharmacological inhibition of Src family kinases by the specific inhibitor PP2 strongly interfered with adhesion, spreading and migration of PET cell lines. Accordingly, the actin cytoskeleton was profoundly altered after inhibition of Src kinases, whereas even prolonged incubation with PP2 exerted no effect on cell cycle progression and/or apoptosis of PET cells. A transient increase in tyrosine phosphorylation of a subset of proteins was observed in QGP-1 cells adhering to the plate, with a peak at 75 min after seeding, when approximately 80% of cells were attached. Inhibition of Src kinases caused a dramatic reduction in the phosphorylation of proteins with different molecular weight that were isolated from the cell extracts by anti-phosphotyrosine immunoprecipitation or pull-down with the SH2 domain of Src. Among them, the docking protein p130Cas interacted with Src and is a major substrate of the Src kinases in QGP-1 cells undergoing adhesion. Our results suggest that Src kinases play a specific role during adhesion, spreading and migration of PET cells and may indicate therapeutical approaches directed to limiting the metastatic potential of these cells.

This article has been cited by other articles:

				Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, and Y. Lu Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 301 - 310. [Abstract] [Full Text] [PDF]